Oppenheimer Maintains Outperform on Opus Genetics, Raises Price Target to $20

Benzinga Newsdesk www.benzinga.com Positive 87.5%

Neg 0% Neu 0% Pos 87.5%

Oppenheimer analyst Andreas Argyrides maintains Opus Genetics (NASDAQ:IRD) with a Outperform and raises the price target from $10 to $20.